Show simple item record

dc.contributor.authorBruce, Ian N
dc.contributor.authorO'Keeffe, Aidan G
dc.contributor.authorFarewell, Vern
dc.contributor.authorHanly, John G
dc.contributor.authorManzi, Susan
dc.contributor.authorSu, Li
dc.contributor.authorGladman, Dafna D
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorSanchez-Guerrero, Jorge
dc.contributor.authorRomero-Diaz, Juanita
dc.contributor.authorGordon, Caroline
dc.contributor.authorWallace, Daniel J
dc.contributor.authorClarke, Ann E
dc.contributor.authorBernatsky, Sasha
dc.contributor.authorGinzler, Ellen M
dc.contributor.authorIsenberg, David A
dc.contributor.authorRahman, Anisur
dc.contributor.authorMerrill, Joan T
dc.contributor.authorAlarcón, Graciela S
dc.contributor.authorFessler, Barri J
dc.contributor.authorFortin, Paul R
dc.contributor.authorPetri, Michelle
dc.contributor.authorSteinsson, Kristjan
dc.contributor.authorDooley, Mary Anne
dc.contributor.authorKhamashta, Munther A
dc.contributor.authorRamsey-Goldman, Rosalind
dc.contributor.authorZoma, Asad A
dc.contributor.authorSturfelt, Gunnar K
dc.contributor.authorNived, Ola
dc.contributor.authorAranow, Cynthia
dc.contributor.authorMackay, Meggan
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorvan Vollenhoven, Ronald F
dc.contributor.authorKalunian, Kenneth C
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorLim, Sam
dc.contributor.authorKamen, Diane L
dc.contributor.authorPeschken, Christine A
dc.contributor.authorInanc, Murat
dc.contributor.authorUrowitz, Murray B
dc.date.accessioned2023-02-07T17:12:35Z
dc.date.available2023-02-07T17:12:35Z
dc.date.issued2014-05-16
dc.identifier.citationBruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, Ruiz-Irastorza G, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171. Epub 2014 May 16. PMID: 24834926; PMCID: PMC4552899.en_US
dc.identifier.eissn1468-2060
dc.identifier.doi10.1136/annrheumdis-2013-205171
dc.identifier.pmid24834926
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8285
dc.description.abstractWe studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.
dc.description.abstractThe Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of transition using maximum likelihood estimation in a multistate model. The Kaplan-Meier method estimated the probabilities for time to first increase in SDI score and Cox regression analysis was used to assess mortality.
dc.description.abstractWe recruited 1722 patients; mean (SD) age 35.0 (13.4) years at cohort entry. Patients with damage at enrolment were more likely to have further worsening of SDI (SDI 0 vs ≥1; p<0.001). Age, USA African race/ethnicity, SLEDAI-2K score, steroid use and hypertension were associated with transition from no damage to damage, and increase(s) in pre-existing damage. Male gender (relative transition rates (95% CI) 1.48 (1.06 to 2.08)) and USA Caucasian race/ethnicity (1.63 (1.08 to 2.47)) were associated with SDI 0 to ≥1 transitions; Asian race/ethnicity patients had lower rates of new damage (0.60 (0.39 to 0.93)). Antimalarial use was associated with lower rates of increases in pre-existing damage (0.63 (0.44 to 0.89)). Damage was associated with future mortality (HR (95% CI) 1.46 (1.18 to 1.81) per SDI point).
dc.description.abstractDamage in SLE predicts future damage accrual and mortality. We identified several potentially modifiable risk factors for damage accrual; an integrated strategy to address these may improve long-term outcomes.
dc.language.isoenen_US
dc.relation.urlhttps://ard.bmj.com/content/74/9/1706.longen_US
dc.rightsPublished by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectCorticosteroidsen_US
dc.subjectInflammationen_US
dc.subjectOutcomes researchen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.titleFactors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleAnnals of the rheumatic diseasesen_US
dc.source.volume74
dc.source.issue9
dc.source.beginpage1706
dc.source.endpage13
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryCanada
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryEngland
dc.description.versionVoRen_US
refterms.dateFOA2023-02-07T17:12:35Z
html.description.abstractWe studied damage accrual and factors determining development and progression of damage in an international cohort of systemic lupus erythematosus (SLE) patients.
html.description.abstractThe Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort recruited patients within 15 months of developing four or more 1997 American College of Rheumatology (ACR) criteria for SLE; the SLICC/ACR damage index (SDI) was measured annually. We assessed relative rates of transition using maximum likelihood estimation in a multistate model. The Kaplan-Meier method estimated the probabilities for time to first increase in SDI score and Cox regression analysis was used to assess mortality.
html.description.abstractWe recruited 1722 patients; mean (SD) age 35.0 (13.4) years at cohort entry. Patients with damage at enrolment were more likely to have further worsening of SDI (SDI 0 vs ≥1; p<0.001). Age, USA African race/ethnicity, SLEDAI-2K score, steroid use and hypertension were associated with transition from no damage to damage, and increase(s) in pre-existing damage. Male gender (relative transition rates (95% CI) 1.48 (1.06 to 2.08)) and USA Caucasian race/ethnicity (1.63 (1.08 to 2.47)) were associated with SDI 0 to ≥1 transitions; Asian race/ethnicity patients had lower rates of new damage (0.60 (0.39 to 0.93)). Antimalarial use was associated with lower rates of increases in pre-existing damage (0.63 (0.44 to 0.89)). Damage was associated with future mortality (HR (95% CI) 1.46 (1.18 to 1.81) per SDI point).
html.description.abstractDamage in SLE predicts future damage accrual and mortality. We identified several potentially modifiable risk factors for damage accrual; an integrated strategy to address these may improve long-term outcomes.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalAnnals of the rheumatic diseases


Files in this item

Thumbnail
Name:
1706.full.pdf
Size:
920.1Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Except where otherwise noted, this item's license is described as Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.